◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › M › MEGA

Mega Lifesciences Public Company Limited (MEGA) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-08-22

Mega Lifesciences Public Company Limited (MEGA) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Bangkok, Thailand. Its market capitalization is roughly THB 32 billion. In the fiscal year ended 2025-12-31, MEGA reported THB 14.1B in revenue and THB 1.9B in net income.

Mega Lifesciences Public Company Limited, together with its subsidiaries, manufactures and sells health food supplements, prescription pharmaceutical products, over-the-counter products, herbal products, vitamins, and fast-moving consumer goods.

Interactive charts & full statements →

MEGA Revenue & Earnings History — Annual Income Statement

Income statement	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total Revenue	THB 14.1B	THB 15.3B	THB 15.7B	THB 15.7B	—
Gross Profit	THB 7.4B	THB 7.8B	THB 7.1B	THB 7.0B	—
Operating Income (EBIT)	THB 2.9B	THB 3.4B	THB 2.9B	THB 2.7B	—
Net Income	THB 1.9B	THB 2.0B	THB 2.0B	THB 2.2B	—

THB; THBM / THBB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

MEGA Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31
Total Revenue	THB 3.4B	THB 3.7B	THB 3.9B	THB 3.4B	THB 3.2B
Gross Profit	THB 1.8B	THB 2.0B	THB 2.0B	THB 1.7B	THB 1.7B
Operating Income (EBIT)	THB 734M	THB 780M	THB 924M	THB 589M	THB 610M
Net Income	THB 604M	THB 577M	THB 494M	THB 391M	THB 450M

THB; THBM / THBB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

MEGA Free Cash Flow History

Cash flow	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Dividends Paid	(THB 1.4B)	(THB 1.4B)	(THB 1.4B)	(THB 1.4B)	—

THB; THBM / THBB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

MEGA Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31
Dividends Paid	THB 0M	(THB 0M)	(THB 698M)	(THB 697M)	THB 0M	—

THB; THBM / THBB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

MEGA Balance Sheet History

Balance sheet	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total Assets	THB 15.8B	THB 14.2B	THB 14.1B	THB 14.6B	—
Total Liabilities	THB 5.5B	THB 4.3B	THB 4.8B	THB 5.9B	—

THB; THBM / THBB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive MEGA viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

GALD · GALDERMA GROUP N — CHF 39 billion
4577 · Daito Pharmaceutical Co.,Ltd. — JPY 37 billion
HLN · Haleon plc — £33 billion
4595 · Mizuho Medy Co.,Ltd. — JPY 33 billion
9273 · Koa Shoji Holdings Co.,Ltd. — JPY 32 billion
2096 · Simcere Pharmaceutical Group Limited — HK$32 billion
SDZ · Sandoz Group AG — CHF 31 billion
3320 · China Resources Pharmaceutical Group Limited — HK$30 billion

← MEEQ All “M” companies MEGI →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.